NCT02320292View on ClinicalTrials.gov

Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

PHASE3TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 11, 2015

Primary Completion Date

February 28, 2021

Study Completion Date

November 9, 2023

Conditions
Ann Arbor Stage I Grade 1 Follicular LymphomaAnn Arbor Stage I Grade 2 Follicular LymphomaAnn Arbor Stage II Grade 1 Contiguous Follicular LymphomaAnn Arbor Stage II Grade 1 Non-Contiguous Follicular LymphomaAnn Arbor Stage II Grade 2 Contiguous Follicular LymphomaAnn Arbor Stage II Grade 2 Non-Contiguous Follicular LymphomaAnn Arbor Stage III Grade 1 Follicular LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage IV Grade 1 Follicular LymphomaAnn Arbor Stage IV Grade 2 Follicular Lymphoma
Interventions
OTHER

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Rituximab

Given IV

RADIATION

Yttrium Y-90 Ibritumomab Tiuxetan

Given IV

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER